Ergoteles’s Rigel Pharmaceuticals RIGL Stock Holding History

Ergoteles’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-13,716	Closed	-$410K	–	1943
2022 Q1	$410K	Buy	13,716 +5,889	+75%	+$159K	0.02%	740
2021 Q4	$207K	Buy	+7,827	New	+$236K	0.01%	1014
2021 Q3	–	Sell	-2,640	Closed	-$115K	–	1600
2021 Q2	$115K	Buy	+2,640	New	+$99.7K	﹤0.01%	1377
2020 Q4	–	Sell	-2,340	Closed	-$56K	–	877
2020 Q3	$56K	Buy	+2,340	New	+$57.5K	0.01%	552

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's RIGL Position: Q2 2022 in Review

Ergoteles sold out of Rigel Pharmaceuticals (RIGL) in Q2 2022, closing a stake of 13,716 shares — an estimated $410K sold.

Ergoteles first reported a position in RIGL in Q3 2020 and held it in 4 quarters. The position peaked at $410K in Q1 2022. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2022.

Ergoteles reported no remaining Rigel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Ergoteles sold 13,716 Rigel Pharmaceuticals shares in Q2 2022, an estimated $410K.
Ergoteles first reported a position in Rigel Pharmaceuticals in Q3 2020 and held it in 4 quarters.
Ergoteles's Rigel Pharmaceuticals position peaked at $410K in Q1 2022.
135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2022.

Based on Ergoteles's 13F filing for Q2 2022, filed 12 Aug 2022.